AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1535568
Drug: Cilazapril 5
RxNorm normalized name: cilazapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 5 mg b.i.d. for 6 months
Trial: 30118368
Drug: m‐AIP (intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐AIP (intrathecal injection of m‐AIP, a specific antagonist of CaMKII)
Trial: 30118368
Drug: m‐AIP (postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐AIP (postoperative treatment)
Trial: 20708966
Drug: IRIS (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRIS (irinotecan plus oral S-1)
Trial: 20708966
Drug: FOLFIRI (folinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (folinic acid and irinotecan plus bolus and continuous infusion of fluorouracil)
Trial: 369006
Drug: Chronic injection
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic injection group (sclerotherapy with ethanolamine oleate)
Trial: 31020334
Drug: Twice-daily concurrent
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily concurrent chemoradiation
Trial: 31020334
Drug: Once-daily concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily concurrent chemoradiation
Trial: 28431278
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (50IU in solution)
Trial: 25599708
Drug: Hyperinsulinemic hypoglycemia
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic hypoglycemia (HH) - bolus insulin 0.1 IE/kg i.v.
Trial: 25599708
Drug: Hyperinsulinemic euglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic euglycemia (HE) - bolus insulin 0.1 IE/kg i.v. and glucose 20% i.v. for 105 min
Trial: 23805994
Drug: Lithium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (0.5 to 0.8 mEq/l)
Trial: 23805994
Drug: Aripiprazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (10 or 15 mg)
Trial: 21831726
Drug: Liprotamase (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liprotamase (5 capsules per day, one capsule with each meal and snack)
Trial: 21831726
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 capsule taken with meals and snacks)
Trial: 15583526
Drug: Lifestyle changes,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle changes, antidepressants, alpha‐2 agonists, anticonvulsants, phytoestrogens, dietary supplements
Trial: 11744586
Drug: 3-in-1 FNB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-in-1 FNB using 30 mL of ropivacaine 0.25%
Trial: 11744586
Drug: 3-in-1 FNB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-in-1 FNB using 30 mL of ropivacaine 0.5%
Trial: 11744586
Drug: 3-in-1 FNB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-in-1 FNB using 30 mL of bupivacaine 0.25%
Trial: 9378180
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccination in addition to usual EPI vaccines
Trial: 9378180
Drug: Usual EPI
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual EPI vaccines (BCG, DTP, OPV, measles, yellow fever)
Trial: 28256051
Drug: OASIS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OASIS plus standard therapy
Trial: 28256051
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) therapy
Trial: 24007452
Drug: mHealth based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth based remote medication adherence measurement system (mAMS)
Trial: 11120525
Drug: 125 mL
RxNorm normalized name: 125 ML argatroban 1 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mL intravenous fluids per hour
Trial: 11120525
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL intravenous fluids per hour
Trial: 8250653
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (25 mg of nicotine per 24 hours for 4 weeks, then 1 patch per day for 2 weeks)
Trial: 31112512
Drug: Ropivacaine 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 3.75 mg/mL (n=25)
Trial: 31112512
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 9 mg/mL) (n=25)
Trial: 23724529
Drug: Ankaferd blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankaferd blood stopper (ABS) - 4 ml spray solution (1 ml/puff X 4) applied topically
Trial: 23724529
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution (0.9% NaCl) - 4 ml applied topically
Trial: 15529389
Drug: DHEA 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 200 mg/day for 1 year
Trial: 10155090
Drug: c7E3 Fab
RxNorm normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: c7E3 Fab (0.25 mg/kg bolus and 10 micrograms/min infusion for 12 hours)
Trial: 2892729
Drug: 15‐methyl‐PGF2 alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15‐methyl‐PGF2 alpha (Prostin 15M), 0.25 mg every second hour
Trial: 2892729
Drug: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonylamide (Nalodor), 0.5 mg every fourth hour
Trial: 28958437
Drug: Clobazam 40
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam 40 mg/d
Trial: 28958437
Drug: Clobazam 160
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam 160 mg/d
Trial: 17328944
Drug: Bradykinin (BK)
RxNorm normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin (BK) administered at graded doses (0.2, 0.6, and 2.0 microg/min)
Trial: 17328944
Drug: Papaverine (PA)
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Papaverine (PA) administered at 12 mg
Trial: 11715357
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ramipril
Trial: 3138131
Drug: Amiloride (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (15 mg p.o.)
Trial: 26152693
Drug: Mixed group
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed group of other glaucoma medications (S2)
Trial: 24092827
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (1 mg/d)
Trial: 21345418
Drug: Enhanced Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Cognitive Behaviour Therapy (CBT‐E), average of 20‐40 individual sessions with a clinical psychologist
Trial: 21345418
Drug: Enhanced Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Cognitive Behaviour Therapy (CBT‐E)
Trial: 18603204
Drug: Elective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective treatment of the neck lymphatics
Trial: 18543684
Drug: Systane treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systane treatment (Group A)
Trial: 18543684
Drug: Purified water
RxNorm normalized name: Purified water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified water treatment (Group B)
Trial: 15605331
Drug: Home exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home exercise program (12-week duration, including hip flexion range of motion exercises, strengthening exercises for bilateral hip flexors, extensors, and abductors, and a daily 30-minute walk)
Trial: 30946851
Drug: Oral agents
RxNorm normalized name: DENTAL AND ORAL AGENTS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agents including sulphonylurea
Trial: 26299164
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid (LAc) treatment in low P diet
Trial: 26299164
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid (CAc) treatment in low P diet
Trial: 26299164
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid (LAc) treatment
Trial: 26299164
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid (CAc) treatment
Trial: 26299164
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid (CAc) and Lactic acid (LAc) treatments
Trial: 24464531
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Naltrexone (50 mg) and Alprazolam (0.5 mg)
Trial: 24464531
Drug: Oral d-amphetamine
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral d-amphetamine (0, 15, and 30 mg)
Trial: 10812285
Drug: Naltrexone (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (0 mg)
Trial: 24464531
Drug: Alprazolam (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0 mg)
Trial: 19554672
Drug: Geriatric Depression
RxNorm normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatric Depression Scale (GDS) administered every 2 weeks for 6 months
Trial: 14982884
Drug: CHOEP (CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOEP (CHOP plus etoposide 100 mg/m2 days 1-3)
Trial: 14982884
Drug: CHOP (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP (standard chemotherapy)
Trial: 11195894
Drug: Anger expression
RxNorm normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anger expression (e.g., President Clinton expressing anger about the Monica Lewinsky scandal)
Trial: 11195894
Drug: Sadness expression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sadness expression (e.g., President Clinton expressing sadness about the Monica Lewinsky scandal)
Trial: 9625131
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg mesalazine b.i.d.
Trial: 9625131
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg mesalazine u.i.d.
Trial: 3310626
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g suspension every four hours)
Trial: 3310626
Drug: Antacid (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (administered every two hours)
Trial: 19923038
Drug: 15-30 mg
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15-30 mg pioglitazone daily (n=21, pioglitazone group)
Trial: 19946230
Drug: L-arginine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (2 g tid for 3 months)
Trial: 17461852
Drug: Intramuscular ALCAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ALCAR 500 mg bid for 14 days followed by oral ALCAR 1000 mg bid for 42 days
Trial: 17461852
Drug: Intramuscular ALCAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ALCAR
Trial: 17461852
Drug: Oral ALCAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ALCAR
Trial: 9367461
Drug: Bivalent live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent live attenuated influenza A virus vaccine (CAV)
Trial: 9367461
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza virus vaccine (TVV)
Trial: 9367461
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza virus vaccine (TVV) and intranasal placebo
Trial: 9367461
Drug: Combination vaccine
RxNorm normalized name: Hepatitis vaccine combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vaccine regimen (CAV and TVV)
Trial: 9367461
Drug: TVV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVV and intranasal placebo
Trial: 3895150
Drug: Tracheal instillation
RxNorm normalized name: bovine type II collagen (tracheal cartilage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tracheal instillation of surfactant (3 or 4 mL, prepared from calf lung lavage)
Trial: 22459543
Drug: 0.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL/kg autologous blood (Group A)
Trial: 22459543
Drug: 1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL/kg autologous blood (Group B)
Trial: 22459543
Drug: 2 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL/kg autologous blood (Group C)
Trial: 22459543
Drug: 1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL/kg normal saline (Group D)
Trial: 15933967
Drug: Postoperative supplemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative supplemental oxygen (8 L/min for 6 hours)
Trial: 15933967
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care (5 L/min oxygen in PACU, no supplemental oxygen on the ward)
Trial: 11071800
Drug: abciximab with
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab with reduced dose reteplase (5+5 U)
Trial: 11071800
Drug: abciximab with
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab with reduced dose reteplase (10+5 U)
Trial: 11071800
Drug: standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard dose reteplase (10+10 U)
Trial: 11071800
Drug: abciximab with
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab with reduced dose reteplase (5+5 U or 10+5 U)
Trial: 1533771
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 to 10 mg/day)
Trial: 1533771
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 to 200 mg/day)
Trial: 31141081
Drug: Optimized calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized calorie and high protein nutrition therapy (2.0 to 2.2g/kg/day protein)
Trial: 31141081
Drug: Optimized calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized calorie and high protein nutrition therapy
Trial: 30543657
Drug: Sanofi Pasteur
RxNorm normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanofi Pasteur recombinant, live, attenuated, tetravalent vaccine (CYD‐TDV)
Trial: 25297613
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber materials (DFMs) including polydextrose, partially hydrolysed guar gum, resistant maltodextrin, partially hydrolysed alginate, glucomannan, heat‐moisture treatment, high‐amylose cornstarch, cellulose
Trial: 20530317
Drug: Armodafinil 150
RxNorm normalized name: armodafinil 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 150 mg/d
Trial: 9164520
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Endoscopic Variceal Ligation + EIS)
Trial: 7970945
Drug: Rhesus-human reassortant
RxNorm normalized name: human-bovine reassortant rotavirus strain G4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus-human reassortant tetravalent oral rotavirus vaccine (4 x 10^4 plaque-forming units)
Trial: 3556051
Drug: Salbutamol from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol from metered-dose inhaler (MDI)
Trial: 1978667
Drug: Flumazenil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (20 mg)
Trial: 1125653
Drug: Plasma immunoreactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma immunoreactive beta‐melanocyte stimulating hormone (beta‐MSH) concentrations
Trial: 31726714
Drug: Winter ice-cream
RxNorm normalized name: winter savory oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Winter ice-cream intake
Trial: 31726714
Drug: Milk-based desserts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based desserts (no winter ice cream)
Trial: 26004031
Drug: 6-week program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week program of enhanced physiotherapy and structured exercise (PEPSE) and essential amino acid supplement drink (glutamine and essential amino acid mixture [GEAA])
Trial: 26004031
Drug: GEAA supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEAA supplement with PEPSE
Trial: 26004031
Drug: Control supplement/PEPSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control supplement/PEPSE
Trial: 26004031
Drug: GEAA supplement/PEPSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEAA supplement/PEPSE
Trial: 24229738
Drug: GeneSight pharmacogenomic-informed
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GeneSight pharmacogenomic-informed treatment (n=26)
Trial: 24229738
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) (n=25)
Trial: 8487513
Drug: Drug and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug and alcohol abuse prenatal care health education program
Trial: 3324648
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 or 60 mg)
Trial: 3324648
Drug: Maprotiline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (75 or 150 mg)
Trial: 20978447
Drug: 7.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/kg bevacizumab
Trial: 20978447
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg bevacizumab
Trial: 16322492
Drug: FNS‐IM (Functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNS‐IM (Functional Neuromuscular Stimulation using intramuscular electrodes)
Trial: 11286465
Drug: Megestrol 160
RxNorm normalized name: megestrol acetate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol 160 mg day(-1)
Trial: 9240185
Drug: tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin (0.2 mg/day)
Trial: 9240185
Drug: allylestrenol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allylestrenol (50 mg/day)
Trial: 8214993
Drug: Lovastatin, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin, 80 mg/day
Trial: 3312862
Drug: Sunscreen cream
RxNorm normalized name: GLYCERIN 1 g in 50 g TOPICAL CREAM [SUNSCREEN Cream]
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen cream (Pabafil SPF 10, with absorption range from 290 to 360 nm)
Trial: 3312862
Drug: Sunscreen cream
RxNorm normalized name: GLYCERIN 1 g in 50 g TOPICAL CREAM [SUNSCREEN Cream]
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen cream
Trial: 24738609
Drug: Tapentadol PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol PR (500 mg/day)
Trial: 24738609
Drug: Tapentadol PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol PR (300 mg/day) / Pregabalin (300 mg/day)
Trial: 23672789
Drug: Pitavastatin 2‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2‐4 mg/day
Trial: 23672789
Drug: Atorvastatin 10‐20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10‐20mg/day
Trial: 21732669
Drug: Selenium-fortified broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-fortified broccoli (200 g daily for 4 weeks)
Trial: 21732669
Drug: Regular broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular broccoli (200 g daily for 4 weeks)
Trial: 16874778
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) administered at weeks 0, 2, 6, and every 6 weeks thereafter through week 24
Trial: 10837017
Drug: Rye crispbread
RxNorm normalized name: Rye
DrugBank: Rye (DB10564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rye crispbread (76.5 g/day for 2 weeks)
Trial: 8780091
Drug: Standard carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard carbidopa/levodopa (Std‐L)
Trial: 8780091
Drug: Sustained-release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release carbidopa/levodopa (L‐CR)
Trial: 1473430
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 micrograms four times daily with meals and at bedtime)
Trial: 30888118
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance treatment (375 mg/m2 q3 months for 2 years)
Trial: 26840703
Drug: Intracutaneous sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous sterile water injections (ISWI)